Home Cart Sign in  
Chemical Structure| 20324-87-2 Chemical Structure| 20324-87-2

Structure of AMI-1
CAS No.: 20324-87-2

Chemical Structure| 20324-87-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AMI-1 is an inhibitor of protein arginine N-methyltransferases (PRMTs) with IC50 of 8.8 μM for PRMT1 via blocking peptide-substrate binding.

Synonyms: AMI-1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AMI-1

CAS No. :20324-87-2
Formula : C21H14N2Na2O9S2
M.W : 548.45
SMILES Code : O=C(NC1=CC2=CC(S(=O)([O-])=O)=CC(O)=C2C=C1)NC3=CC4=CC(S(=O)([O-])=O)=CC(O)=C4C=C3.[Na+].[Na+]
Synonyms :
AMI-1
MDL No. :MFCD00068249
InChI Key :MOUNHKKCIGVIDI-UHFFFAOYSA-L
Pubchem ID :88489

Safety of AMI-1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of AMI-1

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
KM12 cells 1.2 mM 48 h AMI-1 treatment significantly reduced NONO aDMA level PMC7892343
HCT8 cells 0.6 mM 48 h AMI-1 treatment significantly reduced NONO aDMA level PMC7892343
Rh30 cells 129.9 µM 72 h To evaluate the effect of AMI-1 on the proliferation and viability of Rh30 cells, results showed that AMI-1 significantly reduced cell proliferation and viability. PMC8348967
RD cells 123.9 µM 72 h To evaluate the effect of AMI-1 on the proliferation and viability of RD cells, results showed that AMI-1 significantly reduced cell proliferation and viability. PMC8348967
mouse spleen cells 100 µM To evaluate the cytotoxicity of AMI-1 on mouse spleen cells, results showed no cytotoxicity at 100 µM PMC5440547
Tregs 100 µM 3 days To evaluate the effect of AMI-1 on Foxp3 expression in Tregs, results showed that AMI-1 treatment increased the percentage of CD4+Foxp3+ T cells PMC5440547
SKOV3 cells 200 μM 24, 48, 72 h To evaluate the effect of PRMT1 inhibition on BRD4 phosphorylation, results showed that AMI-1 treatment significantly reduced the phosphorylation level of BRD4. PMC10517134
A2780 cells 200 μM 24, 48, 72 h To evaluate the effect of PRMT1 inhibition on BRD4 phosphorylation, results showed that AMI-1 treatment significantly reduced the phosphorylation level of BRD4. PMC10517134
HEK293T cells 200 μM 24, 48, 72 h To evaluate the effect of PRMT1 inhibition on BRD4 phosphorylation, results showed that AMI-1 treatment significantly reduced the phosphorylation level of BRD4. PMC10517134

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice Colorectal cancer xenograft model Intratumoral injection 0.5 mg Once daily for 7 days AMI-1 treatment significantly reduced tumor volume PMC7892343
C57BL/6 J-ApcMin/+ mice DSS-induced colon cancer model Intraperitoneal injection 10 mg/kg Twice weekly, until day 150 AMI-1 treatment significantly reduced the formation of colorectal adenomas in C57BL/6J-ApcMin/+mice and improved the survival rate of the mice. PMC8048298
mice DSS-induced colitis model intraperitoneal injection 200 mg/kg once daily for 7 days To evaluate the therapeutic effect of AMI-1 on DSS-induced colitis model, results showed that AMI-1 treatment reduced disease severity and increased Tregs frequency and function PMC5440547

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01103518 Amenorrhea Dy... More >>smenorrhea Menstruation Disturbances Hyperandrogenism Less << Phase 4 Unknown January 2011 Brazil ... More >> Hospital das Clínicas de Teresópolis Teresópolis, Rio de Janeiro, Brazil, 25976-016 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.82mL

0.36mL

0.18mL

9.12mL

1.82mL

0.91mL

18.23mL

3.65mL

1.82mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories